Molecular structure of JNJ-38877605, CAS Number: 943540-75-8
JNJ-38877605 (CAS 943540-75-8)
See product citations (1)
Application:
JNJ-38877605 is an ATP-competitive inhibitor for the catalytic activity of Met
CAS Number:
943540-75-8
Molecular Weight:
377.35
Molecular Formula:
C19H13F2N7
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
JNJ-38877605 is an ATP-competitive inhibitor for the catalytic activity of Met (IC50 = 4 nM).
JNJ-38877605 (CAS 943540-75-8) References
- Ron kinase transphosphorylation sustains MET oncogene addiction. | Benvenuti, S., et al. 2011. Cancer Res. 71: 1945-55. PMID: 21212418
- Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. | De Bacco, F., et al. 2011. J Natl Cancer Inst. 103: 645-61. PMID: 21464397
- Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. | Pennacchietti, S., et al. 2014. Cancer Res. 74: 6598-609. PMID: 25217525
- The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. | Lolkema, MP., et al. 2015. Clin Cancer Res. 21: 2297-2304. PMID: 25745036
- Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. | Li, W., et al. 2015. Int J Clin Exp Med. 8: 6563-7. PMID: 26131286
- C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. | D'Amico, L., et al. 2016. Oncotarget. 7: 45525-45537. PMID: 27322553
- Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro. | Rebouissou, S., et al. 2017. Clin Cancer Res. 23: 4364-4375. PMID: 28246274
- Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. | Owusu, BY., et al. 2017. Oncotarget. 8: 63014-63025. PMID: 28968967
- Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. | Virzì, AR., et al. 2018. Proc Natl Acad Sci U S A. 115: 10058-10063. PMID: 30224486
- Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met. | Zaky, MY., et al. 2020. Arch Biochem Biophys. 680: 108239. PMID: 31881189
Inhibitor of:
EDG-4, EphB4, HGF, MACC1, Met, and Tyrosine Kinase.Activator of:
LALP70.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JNJ-38877605, 2 mg | sc-364516 | 2 mg | $126.00 | |||
JNJ-38877605, 10 mg | sc-364516A | 10 mg | $365.00 |